« Zurück
Startseite /
Recombinant Monkeypox Virus IFN-alpha/beta-receptor-like Secreted Glycoprotein B16R

Recombinant Monkeypox Virus IFN-alpha/beta-receptor-like Secreted Glycoprotein B16R

ArtNr	230-30236-100
Hersteller	Raybiotech
Menge	100 ug
Kategorie	Peptides & Proteins Recombinant Proteins Immunoprecipitation Western Blot ELISA Immunostaining Dot Blot
Typ	Proteins Recombinant
Format	Liquid
Applikationen	WB, IP, ELISA, Dot
Specific against	Virus, Monkeypox
Host	HEK293 cells
Konjugat/Tag	HIS
Purity	>90%
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Applications	Functional Assay, Protein-protein Interaction, Post-translational Modifications, ELISA, EIA, Western Blotting, Dot Blotting, Immunoprecipitation, Protein Array, etc.
Manufacturer - Category	Proteins\|Recombinant Proteins\|Viral Proteins
Manufacturer - Conjugate / Tag	C-terminal His-tag
Shipping Temperature	Blue ice
Storage Conditions	-20°C
Molecular Weight	Recombinant protein product has a calculated molecular mass of ∼38 kDa. Due to the abundant glycosylation, it migrates as approximately ∼50 Da protein bands in SDS-PAGE under DTT, beta-mercaptoethanol reducing conditions.
Description	Recombinant Monkeypox virus IFN-alpha/beta-receptor-like secreted glycoprotein (B16R) with a C-terminal His-tag, derived from the transfected HEK293 cells.
Purity determined by	SDS-PAGE under reducing conditions and visualized by Coomassie blue staining
Gene Symbols	B16R
UNSPSC Code	12352202
Formulation	Filtered solution in PBS with 1% mannitol and 5% trehalose
Expressed Region	His21-Glu352
Purification	His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC)
Concentration	Determined by BCA protein assay
Endotoxin Level	<0.5 EU per µg of the protein as determined by the LAL method
SDS-PAGE Image	Figure 1. Deglycosylation analysis of purified recombinant proteins. The same amount of purified proteins were untreated (Lane 2) or treated with protein deglycosylation enzymes under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one reduced band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated.Lane 1: protein standard ladder (kDa).Lane 2: untreated protein.Lane 3: treated protein with deglycosylation enzymes under native conditions.Lane 4: treated protein with deglycosylation enzymes under denature conditions.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.